Dr. Trinklein is currently Chief Technology Officer at Teneobio. His group employs a novel sequence-based approach for antibody discovery and lead identification that leverages next-gen sequence and high-throughput recombinant expression to screen large numbers of diverse sequence-defined antibodies. Prior to Teneobio, Dr. Trinklein was co-founder and CEO of SwitchGear Genomics, a venture-backed company that was acquired in 2013. SwitchGear developed and commercialized a unique cell-based platform for small molecule pathway screening. Dr. Trinklein served as the Technical Director of the Stanford ENCODE project and received his Ph.D from Stanford University. Dr. Trinklein has published over 20 peer-reviewed papers and is an inventor on over 15 patents.